IPP Bureau
Gilead’s new HIV therapy shows promising Phase 3 results
By IPP Bureau - December 19, 2025
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial
By IPP Bureau - December 19, 2025
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
Takeda joins BaseLaunch to boost early-stage biotech ventures in Europe
By IPP Bureau - December 19, 2025
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Roche unveils major upgrade to cobas 6800/8800 systems, boosting lab efficiency
By IPP Bureau - December 19, 2025
The update promises to revolutionize laboratory workflows by optimizing resources
Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder
By IPP Bureau - December 19, 2025
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
SABIC launches first fluorine-free polycarbonate resin to boost medical device safety
By IPP Bureau - December 19, 2025
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
ystral expands in India with new Bangalore facility, boosting team & local production
By IPP Bureau - December 19, 2025
The expansion includes a larger technical and service team and increased local procurement
Novo Nordisk files FDA application for once-weekly obesity drug CagriSema
By IPP Bureau - December 19, 2025
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
JHS Svendgaard to invest Rs. 25 crore on building new manufacturing unit
By IPP Bureau - December 19, 2025
The new facility is expected to generate 500-600 new jobs in the region
Max Healthcare announces Rs.1,000-cr foray into Pune with 450-bed super speciality hospital
By IPP Bureau - December 19, 2025
The state-of-the-art facility is expected to be commissioned over the next three years
Eli Lilly reports positive Phase 3 results for oral obesity drug Orforglipron
By IPP Bureau - December 19, 2025
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
GenSci, RTW & Yarrow Bioscience strike $1.365 billion global deal for breakthrough graves’ disease therapy
By IPP Bureau - December 19, 2025
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
Agilent Technologies opens India Refurbishment Center
By IPP Bureau - December 19, 2025
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
,_Thyrocare.jpg "Thyrocare appoints Dr Ramesh Kinha as COO")
Thyrocare appoints Dr Ramesh Kinha as COO
By IPP Bureau - December 19, 2025
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
Lupin receives positive CHMP opinion for biosimilar Ranibizumab
By IPP Bureau - December 18, 2025
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
